Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Platinum and Etoposide Chemotherapy, Durvalumab With Thoracic Radiotherapy in the First Line Treatment of Patients With Extensive-stage Small-cell Lung Cancer

NCT05796089 is registered in ClinicalTrials.gov with Trans Tasman Radiation Oncology Group as lead sponsor.

NCT NCT05796089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05796089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Platinum and Etoposide Chemotherapy, Durvalumab With Thoracic Radiotherapy in the First Line Treatment of Patients With Extensive-stage Small-cell Lung Cancer
Lead sponsor
Trans Tasman Radiation Oncology Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 1, 2022
Completion date
February 28, 2028
Enrollment
35 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small-cell lung cancer